CRVO CERVOMED INC

CervoMed to Participate in the Emerging Growth Conference 67

CervoMed to Participate in the Emerging Growth Conference 67

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company’s Management will provide a corporate update at the Emerging Growth Conference 67, to be held virtually from February 7-8, 2024.

Presentation Details

Format: Corporate presentation

Date: Wednesday, February 7, 2024

Time: 3:50 PM ET

Registration Link:

A live webcast of the presentation, along with accompanying slides, will be accessible . A replay of the presentation will also be available through the conference portal and on the following the event.

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About CervoMed

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

Investor Contact:

PJ Kelleher

LifeSci Advisors



617-430-7579



EN
05/02/2024

Underlying

CRVOCERVOMED INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERVOMED INC

 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Reports First Quarter 2025 Financial Results and Provides Cor...

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities Initiating separate Phase 2a trials to evaluate neflamapimod in patients with primary progressive aphasia and patients in the recovery phase after ischemic stroke BOSTON, May 12, 2025 (GLOBE NEW...

May 12, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Inves...

CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held in New York, NY, on Tuesday, May 20, 2025. Presentation DetailsFormat: Fireside ChatDate: Tuesday, May 20, 2025Time: 5:00 – 5:30 PM...

May 7, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

Investigators to Present Clinical Trial Results Showing Neflamapimod S...

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025 During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC) Neflamapimod was associated with a reduced incidence of falls in the Extension phase of the study and new data to be presented at AD/PD™ 2025 demonstrates improvements on endpoint...

April 2, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Announces Oral Presentation at 19th International Conference ...

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™) BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses...

March 25, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results a...

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates -Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome measure- -Plan to initiate Phase 3 trial in mid-2026 following meeting with regulatory authorities- -Awarded 2024 Prix Galien USA Award as “Best Startup” by the Galien Foundation- BOSTON, March 17, 2025 (GLOBE NEWSWIRE) --  CervoMed Inc. (NASDAQ: CRVO), a clinical stage compan...

March 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch